ES2063365T3 - Composiciones anticoagulantes basadas en el factor xa. - Google Patents

Composiciones anticoagulantes basadas en el factor xa.

Info

Publication number
ES2063365T3
ES2063365T3 ES90909958T ES90909958T ES2063365T3 ES 2063365 T3 ES2063365 T3 ES 2063365T3 ES 90909958 T ES90909958 T ES 90909958T ES 90909958 T ES90909958 T ES 90909958T ES 2063365 T3 ES2063365 T3 ES 2063365T3
Authority
ES
Spain
Prior art keywords
factor
inactivated
vivo
active
serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90909958T
Other languages
English (en)
Inventor
Charles T Esmon
Fletcher B Taylor Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of ES2063365T3 publication Critical patent/ES2063365T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

UN COMPUESTO ANTICOAGULANTE QUE CONTIENE UNA CANTIDAD EFECTIVA DEL FACTOR XA PROVISTO DE UN LUGAR SEROSO ACTIVO, INACTIVADO QUE FUNCIONA RAPIDA Y EFECTIVAMENTE EN VIVO, PARA SUPRIMIR LA COAGULACION. EN UNA INCORPORACION PREFERENTE, EL FACTOR XA, UNA ESTERASA SEROSA QUE FORMA UN COMPLEJO CON EL FACTOR VA, CA ELEVADO ++, Y FOSFOLIPIDO PARA CATALIZAR LA ACTIVACION DE LA PROTOMBINA, SE ACTIVA PRIMERO CON UN INHIBIDOR DE SITIO ACTIVO, TAL COMO AL ACETONA CLOROMETIL-ARG-GLI-GLU-DENSILA, PARA FORMAR UN FACTOR XA DESACTIVADO. EN OTRA INCORPORACION, EL FACTOR XA SE EXPRESA DESDE UNA SECUENCIA GENETICA DONDE SE MODIFICA LA PARTE QUE CODIFICA LA REGION SEROSA ACTIVA. LA PROTEINA INACTIVA RETIENE LA CAPACIDAD DE UNIRSE AL FACTOR ENDOGENO VA EN VIVO, Y TIENE UNA VIDA MEDIA DE APROXIMADAMENTE 10 HORAS. LA ADMINISTRACION DEL FACTOR XA INACTIVO A LA SANGRE DE UN PACIENTE SIN LA FORMACION DE LOS COMPLEJOS DEL FACTOR XA-VA INACTIVO EN VIVO, INHIBEN LA COAGULACION.
ES90909958T 1989-06-14 1990-06-06 Composiciones anticoagulantes basadas en el factor xa. Expired - Lifetime ES2063365T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/367,544 US5120537A (en) 1989-06-14 1989-06-14 Factor xa based anticoagulant compositions

Publications (1)

Publication Number Publication Date
ES2063365T3 true ES2063365T3 (es) 1995-01-01

Family

ID=23447608

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90909958T Expired - Lifetime ES2063365T3 (es) 1989-06-14 1990-06-06 Composiciones anticoagulantes basadas en el factor xa.

Country Status (10)

Country Link
US (1) US5120537A (es)
EP (1) EP0477274B1 (es)
JP (1) JPH0784392B2 (es)
AT (1) ATE101796T1 (es)
AU (1) AU630477B2 (es)
CA (1) CA2060507C (es)
DE (1) DE69006851T2 (es)
DK (1) DK0477274T3 (es)
ES (1) ES2063365T3 (es)
WO (1) WO1990015619A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS136091A3 (en) * 1990-05-10 1992-04-15 Zymo Genetics Agents for determining thrombi and their application
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US20040072757A1 (en) * 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US5266462A (en) * 1992-06-03 1993-11-30 Baxter Diagnostics Inc. Measurement of platelet activities
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
DK0796623T3 (da) * 1996-03-20 2005-08-01 Baxter Ag Farmaceutisk præparat til behandling af blodkoagulationslidelser
WO2001033217A2 (en) * 1999-11-02 2001-05-10 Aventis Pharma Deutschland Gmbh Monitoring the activity of factor xa inhibitors
AU2001257893A1 (en) * 2000-01-13 2001-07-24 Baxter International Inc. Multiple inactivated blood factor anticoagulant composition
US6987127B2 (en) * 2001-12-21 2006-01-17 Charlotte-Mecklenburg Hospital Authority Regulation of NAD(P)H oxidase growth and transcription in melanoma cells
AU2003237870A1 (en) * 2002-06-07 2003-12-22 The Brigham & Women's Hospital, Inc. Method and composition for inhibing or slowing blood coagulation
US7771956B2 (en) * 2003-06-30 2010-08-10 Brigham & Women's Hospital, Inc. Method for detecting the presence of a phospholipid
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
US12073926B2 (en) 2020-09-21 2024-08-27 Instrumentation Laboratory Company Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample
CN119095400B (zh) * 2023-06-06 2025-10-03 华能新能源股份有限公司 一种钙钛矿太阳能电池及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3684947D1 (de) * 1985-03-15 1992-05-27 Nat Res Dev Faktor-ix-protein.
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii

Also Published As

Publication number Publication date
CA2060507C (en) 1996-12-10
WO1990015619A1 (en) 1990-12-27
JPH04505765A (ja) 1992-10-08
DE69006851T2 (de) 1994-06-30
CA2060507A1 (en) 1990-12-15
ATE101796T1 (de) 1994-03-15
JPH0784392B2 (ja) 1995-09-13
EP0477274B1 (en) 1994-02-23
DE69006851D1 (de) 1994-03-31
AU630477B2 (en) 1992-10-29
AU5922690A (en) 1991-01-08
US5120537A (en) 1992-06-09
EP0477274A1 (en) 1992-04-01
DK0477274T3 (da) 1994-03-28

Similar Documents

Publication Publication Date Title
ES2063365T3 (es) Composiciones anticoagulantes basadas en el factor xa.
Rajesh et al. Procoagulant activity of Calotropis gigantea latex associated with fibrin (ogen) olytic activity
Bell Jr Defibrinogenating enzymes
Okajima et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
Elg et al. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor
Bernardes et al. Isolation and structural characterization of a new fibrin (ogen) olytic metalloproteinase from Bothrops moojeni snake venom
FI911049A0 (fi) Vaevnadsplasminogenaktivator med zymogena eller fibrinspecifika egenskaper.
Bajwa et al. Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes
Jagadeesha et al. A non-toxic anticoagulant metalloprotease: purification and characterization from Indian cobra (Naja naja naja) venom
CA2101614A1 (en) Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
GB1533205A (en) Plasmin fractions and complexes thereof
SAWYER et al. Thrombolytic therapy: basic and therapeutic considerations
Kini et al. Inhibition of platelet aggregation by a fibrinogenase from Naja nigricollis venom is independent of fibrinogen degradation
Mosesson Fibrinogen catabolic pathways
Benedict et al. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
Kazama et al. Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4: role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein
Grotto et al. Effect of purified Vipera palestinae hemorrhagin on blood coagulation and platelet function
McNicol Disordered fibrinolytic activity and its control
ATE103178T1 (de) T-pa pro stabilisierung.
DE69105121D1 (de) Gewebeplasminogenaktivator mit fibrin-spezifischen eigenschaften.
Chen et al. Lys-and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation
Ries et al. Influence of soluble fibrin on reaction kinetics of plasmin type 1 and type 2 with α2-antiplasmin
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse
Ariga et al. Studies on thrombin accelerating factor in human urine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 477274

Country of ref document: ES